New 5mg tablet offers the same established efficacy and safety as the Evrysdi oral solution for individuals living with spinal muscular atrophy.

Will significantly enhance service to researchers and institutions across China.

Demonstrates its commitment to safeguarding sensitive information and adhering to global standards.

SK pharmteco, a global contract development and manufacturing organization (CDMO), has launched an enhanced analytical testing laboratory specifically dedicated to High Potency Active Pharmaceutical ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

Alcami Corporation, a contract development and manufacturing organization (CDMO), has appointed pharmaceutical industry ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).